Teva Pharmaceutical Industries - TEVA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.88
  • Forecasted Upside: -4.54%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.33 (-1.95%)

This chart shows the closing price for TEVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Teva Pharmaceutical Industries Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TEVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TEVA

Analyst Price Target is $15.88
▼ -4.54% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Teva Pharmaceutical Industries in the last 3 months. The average price target is $15.88, with a high forecast of $21.00 and a low forecast of $11.00. The average price target represents a -4.54% upside from the last price of $16.63.

This chart shows the closing price for TEVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 8 polled investment analysts is to moderate buy stock in Teva Pharmaceutical Industries. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/5/2024BarclaysBoost TargetOverweight ➝ Overweight$20.00 ➝ $21.00Low
5/30/2024Bank of AmericaBoost TargetBuy ➝ Buy$18.00 ➝ $21.00Low
5/13/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$19.00 ➝ $20.00Low
5/9/2024BarclaysBoost TargetOverweight ➝ Overweight$17.00 ➝ $20.00Low
3/8/2024JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$14.00Low
2/12/2024Piper SandlerUpgradeNeutral ➝ Overweight$12.00 ➝ $19.00Low
2/5/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$10.00 ➝ $11.00Low
2/5/2024BarclaysBoost TargetOverweight ➝ Overweight$15.00 ➝ $17.00Low
1/29/2024BarclaysBoost TargetOverweight ➝ Overweight$14.00 ➝ $15.00Low
1/23/2024Jefferies Financial GroupUpgradeHold ➝ Buy$10.00 ➝ $14.00Low
1/3/2024Piper SandlerUpgradeUnderweight ➝ Neutral$8.00 ➝ $12.00Low
12/18/2023HSBCInitiated CoverageBuy$13.00Low
11/27/2023UBS GroupUpgradeNeutral ➝ Buy$11.00 ➝ $13.00Low
9/20/2023UBS GroupBoost TargetNeutral ➝ Neutral$8.00 ➝ $11.00Low
9/8/2023Bank of AmericaBoost TargetBuy ➝ Buy$12.00 ➝ $13.00Low
7/6/2023UBS GroupUpgradeSell ➝ Neutral$7.00 ➝ $8.00Low
5/25/2023Morgan StanleyInitiated CoverageEqual Weight$10.00Low
5/18/2023Evercore ISIUpgradeIn-Line ➝ OutperformLow
2/9/2023BarclaysBoost TargetOverweight$13.00 ➝ $14.00Low
1/19/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$10.00 ➝ $12.00Low
11/23/2022Piper SandlerLower TargetUnderweight$8.00 ➝ $7.00Low
11/14/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$11.00 ➝ $10.00Low
11/7/2022BMO Capital MarketsLower TargetMarket Perform$11.00 ➝ $10.00Low
11/4/2022UBS GroupDowngradeNeutral ➝ SellLow
10/21/2022Jefferies Financial GroupReiterated RatingBuy$10.00Low
8/5/2022Bank of AmericaUpgradeNeutral ➝ Buy$10.00 ➝ $13.00Low
8/2/2022The Goldman Sachs GroupBoost TargetNeutral$9.00 ➝ $10.00Low
6/13/2022UBS GroupInitiated CoverageNeutral$10.00Low
5/17/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$9.00N/A
5/4/2022Piper SandlerDowngradeNeutral ➝ Underweight$11.00 ➝ $7.00Low
4/5/2022BarclaysUpgradeEqual Weight ➝ Overweight$11.00 ➝ $13.00N/A
3/25/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$11.00Medium
2/18/2022BarclaysLower TargetEqual Weight$13.00 ➝ $11.00Medium
1/27/2022ArgusDowngradeBuy ➝ HoldMedium
10/28/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
7/29/2021Raymond JamesLower TargetOutperform$15.00 ➝ $14.00Medium
7/29/2021Wells Fargo & CompanyLower TargetEqual Weight$12.00 ➝ $11.00Medium
5/10/2021UBS GroupReiterated RatingBuy ➝ Neutral$15.00 ➝ $11.00N/A
5/4/2021UBS GroupDowngradeBuy ➝ Neutral$15.00 ➝ $11.00High
3/14/2021JPMorgan Chase & Co.Reiterated RatingHold$10.00Medium
12/28/2020Raymond JamesReiterated RatingBuyN/A
11/24/2020OppenheimerInitiated CoverageMarket PerformLow
11/6/2020BMO Capital MarketsLower TargetMarket Perform$13.00 ➝ $11.00High
10/23/2020Raymond JamesReiterated RatingBuyLow
10/13/2020ArgusLower TargetAverage ➝ Buy$14.00 ➝ $11.00Low
9/14/2020Raymond JamesReiterated RatingBuyLow
8/26/2020Bank of AmericaReiterated RatingSell$8.00Low
8/6/2020SVB LeerinkBoost TargetMarket Perform$13.00 ➝ $14.00Medium
8/6/2020BarclaysUpgradeUnderweight ➝ Equal Weight$10.00 ➝ $13.00Medium
7/27/2020The Goldman Sachs GroupInitiated CoverageNeutral$12.00Low
6/1/2020SunTrust BanksUpgradeHold ➝ Buy$11.00 ➝ $16.00High
5/11/2020UBS GroupBoost TargetBuy$12.00 ➝ $15.00Medium
5/8/2020Cantor FitzgeraldReiterated RatingNeutralLow
5/8/2020SVB LeerinkBoost TargetMarket Perform$11.00 ➝ $12.00Low
5/8/2020Bank of AmericaReiterated RatingUnderperform$7.00 ➝ $8.00Low
4/24/2020CitigroupInitiated CoverageNeutralLow
4/17/2020BarclaysReiterated RatingSell$9.00Low
4/15/2020Piper SandlerLower TargetNeutral$10.00 ➝ $8.00Low
4/6/2020UBS GroupUpgradeNeutral ➝ Buy$14.00 ➝ $12.00High
4/2/2020Morgan StanleyLower TargetUnderweight$13.00 ➝ $8.00Medium
3/23/2020Bank of AmericaLower TargetUnderperform$11.00 ➝ $7.00Low
3/5/2020Wells Fargo & CompanyBoost TargetEqual Weight$10.00 ➝ $12.00Low
2/24/2020Edward JonesDowngradeHold ➝ SellHigh
2/18/2020ArgusBoost TargetBuy$10.00 ➝ $15.00Low
2/17/2020UBS GroupBoost TargetNeutral$8.00 ➝ $14.00Medium
2/14/2020Morgan StanleyBoost TargetUnderweight$8.00 ➝ $13.00High
2/13/2020Bank of AmericaBoost TargetUnderperform$8.00 ➝ $11.00High
2/13/2020SunTrust BanksBoost TargetHold$9.00 ➝ $13.00Medium
2/13/2020OppenheimerBoost TargetOutperform$12.00 ➝ $16.00High
2/12/2020Cantor FitzgeraldBoost TargetIn-Line ➝ Neutral$9.00 ➝ $15.00Low
2/12/2020CfraBoost TargetHold$11.00 ➝ $13.00Low
1/22/2020Wells Fargo & CompanyBoost TargetEqual Weight$8.00 ➝ $10.00Medium
1/3/2020Bank of AmericaUpgradeUnderperform ➝ BuyHigh
11/12/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$8.00Medium
10/16/2019GabelliUpgradeHold ➝ BuyHigh
9/30/2019Wells Fargo & CompanyLower TargetMarket Perform$17.00 ➝ $8.00Low
9/12/2019GuggenheimInitiated CoverageNeutralLow
9/6/2019JPMorgan Chase & Co.Lower TargetUnderweight$9.00 ➝ $7.00Low
8/16/2019UBS GroupSet TargetHold$8.00High
8/9/2019BMO Capital MarketsLower TargetMarket Perform$11.00 ➝ $9.00N/A
8/8/2019Royal Bank of CanadaReiterated RatingHold$10.00High
8/8/2019SunTrust BanksLower TargetHold$7.00Medium
8/8/2019Raymond JamesLower TargetOutperform$22.00 ➝ $15.00Medium
8/7/2019CowenSet TargetHold$9.00Low
7/19/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer Perform$9.00Low
7/15/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$16.00 ➝ $6.00High
7/10/2019Credit Suisse GroupReiterated RatingNeutralLow
7/5/2019ArgusUpgradeHold ➝ Buy$12.00High
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 6 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 18 very positive mentions
  • 29 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
  • 15 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 15 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 20 very positive mentions
  • 27 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
  • 13 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 13 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Read More

Today's Range

Now: $16.63
Low: $16.56
High: $16.91

50 Day Range

MA: $15.66
Low: $12.78
High: $17.40

52 Week Range

Now: $16.63
Low: $7.42
High: $17.69


3,027,664 shs

Average Volume

10,481,570 shs

Market Capitalization

$18.84 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?

The following sell-side analysts have issued research reports on Teva Pharmaceutical Industries in the last year: Bank of America Co., Barclays PLC, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler,, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for TEVA.

What is the current price target for Teva Pharmaceutical Industries?

8 Wall Street analysts have set twelve-month price targets for Teva Pharmaceutical Industries in the last year. Their average twelve-month price target is $15.88, suggesting a possible downside of 4.5%. Barclays PLC has the highest price target set, predicting TEVA will reach $21.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $11.00 for Teva Pharmaceutical Industries in the next year.
View the latest price targets for TEVA.

What is the current consensus analyst rating for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TEVA.

What other companies compete with Teva Pharmaceutical Industries?

How do I contact Teva Pharmaceutical Industries' investor relations team?

Teva Pharmaceutical Industries' physical mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company's listed phone number is (723) 914-8213 and its investor relations email address is [email protected]. The official website for Teva Pharmaceutical Industries is Learn More about contacing Teva Pharmaceutical Industries investor relations.